Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Preapproval Safe Harbor Should Extend 18 Months, Payers And Sponsors Say

Executive Summary

Manufacturers should be allowed to talk to payer representatives involved in financial forecasting about a new drug well before FDA approval, group led by Academy of Managed Care Pharmacy says.


Related Content

'Safe Harbor' For Preapproval Information Exchange To Get Legislative Push
Alzheimer’s Drugs and Medicare: A Case For Pre-Approval Discussions
FDA's Off-Label Communication Changes Should Start With Payers – PhRMA
Off-Label Debate Between FDA, Industry To Formally Begin After Election
Rx Economic Information-Sharing Concept Getting Renewed Push





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts